drugset

drugset / Trial / NCT06543459

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

NCT06543459 ↗

Phase 1 Not yet recruiting 16 enrolled Wuhan Createrna Science and Technology Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects

Timeline

Start: 2024-08-10
Primary completion: 2024-09-27
Completion: 2024-12-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MY008211A	Unknown	—	Oral

Indications